Atomo Diagnostics Limited Share Price

Equities

AT1

AU0000080327

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 07:10:44 26/04/2024 BST 5-day change 1st Jan Change
0.03 AUD 0.00% Intraday chart for Atomo Diagnostics Limited -3.23% +36.36%

Financials

Sales 2022 12.34M 8.06M 645M Sales 2023 2.54M 1.66M 133M Capitalization 12.56M 8.2M 657M
Net income 2022 -5M -3.27M -261M Net income 2023 -9M -5.88M -471M EV / Sales 2022 1.57 x
Net cash position 2022 12.63M 8.25M 660M Net cash position 2023 6.22M 4.06M 325M EV / Sales 2023 2.49 x
P/E ratio 2022
-5.58 x
P/E ratio 2023
-1.26 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 60.01%
More Fundamentals * Assessed data
Dynamic Chart
1 week-3.23%
Current month-3.23%
3 months+20.00%
6 months+30.43%
Current year+36.36%
More quotes
1 week
0.03
Extreme 0.03
0.03
1 month
0.03
Extreme 0.028
0.04
Current year
0.02
Extreme 0.022
0.06
1 year
0.02
Extreme 0.02
0.10
3 years
0.02
Extreme 0.02
0.37
5 years
0.02
Extreme 0.02
0.63
10 years
0.02
Extreme 0.02
0.63
More quotes
Managers TitleAgeSince
Founder - 31/12/09
Chief Operating Officer - 31/12/16
Members of the board TitleAgeSince
Director/Board Member - 14/11/22
Director/Board Member 71 14/10/21
Director/Board Member 66 -
More insiders
Date Price Change Volume
26/04/24 0.03 0.00% 279,718
24/04/24 0.03 -3.23% 290,416
23/04/24 0.031 +3.33% 655,853
22/04/24 0.03 -3.23% 647,434
19/04/24 0.031 0.00% 124,778

Delayed Quote Australian S.E., April 26, 2024 at 07:10 am

More quotes
Atomo Diagnostics Limited is an Australia-based medical device company. The Company supplies integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The Company’s patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has commercialized a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases, including COVID-19, HIV, viral vs bacterial differentiation and female health. Its products include Atomo HIV Self-Test, AtomoRapid HIV (1&2) and ATOMONOW Pregnancy Test. Its Atomo HIV Self-Test is an integrated, blood-based rapid diagnostic test (RDT) for HIV screening, which provides results in 15 minutes. Its AtomoRapid HIV (1&2) integrates multiple test components into the device platform. AtomoRapid HIV (1&2) needs a small drop of blood to give results in 15 minutes.
More about the company

Annual profits - Rate of surprise